Corresponding Author: Naveen L. Pereira, MD, Department of Cardiovascular Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905 (pereira.naveen@mayo.edu).
Accepted for Publication: June 25, 2020.
Author Contributions: Drs Pereira and Bailey had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Pereira and Farkouh were coprimary first authors.
Concept and design: Pereira, Farkouh, So, Lennon, Mathew, Jeong, Baudhuin, Fu, Goodman, Hasan, Iturriaga, Lerman, Wang, Weinshilboum, Bailey, Rihal.
Acquisition, analysis, or interpretation of data: Pereira, Farkouh, So, Lennon, Geller, Mathew, Bell, Bae, Chavez, Gordon, Abbott, Cagin, Hasan, Lerman, Sidhu, Tanguay, Weinshilboum, Welsh, Rosenberg, Bailey, Rihal.
Drafting of the manuscript: Pereira, Farkouh, So, Lennon, Bae, Jeong, Fu, Hasan, Weinshilboum, Rihal.
Critical revision of the manuscript for important intellectual content: Pereira, Farkouh, So, Lennon, Geller, Mathew, Bell, Chavez, Gordon, Abbott, Cagin, Baudhuin, Goodman, Hasan, Iturriaga, Lerman, Sidhu, Tanguay, Wang, Weinshilboum, Welsh, Rosenberg, Bailey, Rihal.
Statistical analysis: Lennon, Geller, Hasan, Bailey, Rihal.
Obtained funding: Pereira, Farkouh, Lennon, Goodman, Lerman, Wang, Weinshilboum.
Administrative, technical, or material support: Pereira, Mathew, Bae, Jeong, Gordon, Baudhuin, Fu, Goodman, Iturriaga, Weinshilboum, Welsh, Rosenberg, Bailey, Rihal.
Supervision: Pereira, Farkouh, Lennon, Bae, Chavez, Goodman, Tanguay, Weinshilboum, Rosenberg, Bailey, Rihal.
Conflict of Interest Disclosures: Dr Pereira reported receiving grants from the National Heart, Lung, and Blood Institute (NHLBI). Dr Farkouh reported receiving grants from NHLBI, Amgen, Novartis, and Novo Nordisk. Dr So reported receiving grants from Eli Lilly Canada, Spartan Biosciences, Roche Diagnostics, and Aggredyne Inc and receiving personal fees from AstraZeneca Canada, Bayer Canada, and Servier Canada. Dr Lennon reported receiving grants from the National Institutes of Health (NIH)/NHLBI and receiving nonfinancial support from Spartan Biosciences. Dr Abbott reported receiving grants from AstraZeneca, Bristol Myers Squibb, Sino Medical, Biosensors Research USA, Abbott Vascular, and CSL Behring. Dr Goodman reported receiving grants from the Mayo Clinic and NIH; receiving nonfinancial support from Spartan Biosciences; receiving grants and personal fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Eli Lilly Merck, Novartis, Pfizer, and York University Clinical Coordinating Centre; and receiving personal fees from Daiichi-Sankyo/American Regent, Esperion, Ferring Pharmaceuticals, GlaxoSmithKline, HLS Therapeutics, Janssen/Johnson & Johnson, Novo Nordisk A/C, Regeneron, Servier, the Heart and Stroke Foundation of Ontario/University of Toronto (Polo) chair, the Canadian Heart Research Centre and MD Primer, Canadian VIGOUR Centre, Duke Clinical Research Institute, and PERFUSE Research Institute. Dr Lerman reported receiving personal fees from Itamar Medical, Phillips/Volcano, Shahal, and Wei Jian RC Inc. Dr Sidhu reported serving on scientific advisory boards for Sanofi Regeneron and AstraZeneca. Dr Tanguay reported receiving personal fees from Mayo Clinic, AstraZeneca, Bayer, Daiichi-Sankyo, Servier, Novartis, and BMS-Pfizer Alliance. Dr Wang reported receiving grants from NIH and NHLBI. Dr Weinshilboum reported receiving grants from NIH and NHLBI and that he is cofounder of, and stockholder in, OneOme LLC. Dr Welsh reported receiving personal fees from Mayo Clinic; receiving grants from AstraZeneca and Pfizer; and receiving grants and personal fees from Bayer and Boerhinger Ingelheim. Dr Bailey reported receiving grants from NIH. No other disclosures were reported.
Funding/Support: Funding for this research was provided by the NIH (grants U01HL128606 and U01HL128626).
Role of the Funder/Sponsor: The NIH established an independent data and safety monitoring board to monitor adverse events but had no role in the design of the study; collection, management, and interpretation of the data; preparation of the manuscript; or decision to submit the manuscript for publication.
Disclaimer: The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the NHLBI, the NIH, or the US Department of Health and Human Services.
Data Sharing Statement: See Supplement 4.
Additional Contributions: We are grateful for the effort and assistance from Daniel Crusan, BS, Monica Olson, MBA, and Julia Byrne, BS, Mayo Clinic; Spartan, Applied Health Research Centre (AHRC), DREAM CIS, Biospecimens Accessioning and Processing (BAP) at Mayo Clinic, and the TAILOR-PCI clinical trial site principal investigators and their study coordinators. The TAILOR-PCI clinical trial site principal investigators include Khaled Abdul-Nour, MD, Henry Ford Health System; Amir Darki, MD, Loyola University Medical Center; Payam Dehghani, MD, Regina General Hospital; Josh Doll, MD, Greenville Health System; Mohammed El-Hajjar, MD, Albany Medical Center; Jorge Escobedo, MD, Mexico-La Raza, Centro Medico; Adam Frank, MD, NCH Healthcare System; Wilson Ginete, MD, and Alok Bachuwar, MD, Essentia Institute of Rural Health; Ronald Goldberg, MD, Sharp Healthcare Center for Research; John Graham, MD, St. Michael’s Hospital; Cameron Guild, MD, and William Campbell, MD, University of Mississippi Medical Center; Sang Wook Kim, MD, Chung-Ang University Hospital; Louie Kostopoulis, MD, Aurora Research Institute; Gary Lane, MD, Mayo Clinic in Florida; Hong-seok Lim, MD, Ajou University Hospital; Andrea MacDougall, MD, Thunder Bay Regional Research Institute; Mina Madan, MD, Sunnybrook Research Institute; Kevin Marzo, MD, Winthrop University Hospital; Tamim Nazif, MD, Columbia University Medical Center; Fearghas O’Cochlain, MD, Mayo Clinic Health System—Eau Claire Hospital Inc; Christopher Overgaard, MD, and Vlad Dzavik, MD, Toronto General Hospital; Ganesh Raveendran, MD, University of Minnesota; Louai Razzouk, MD, NYU Langone Medical Center; Carl Reimers, MD, and Kirk Garratt, MD, The Feinstein Institute for Medical Research-Lenox Hill; Jorge Saucedo, MD, and Justin Levisay, MD, NorthShore University Health System; Jacqueline Saw, MD, Vancouver General Hospital; D.P. Suresh, MD, St. Elizabeth Healthcare; John Sweeney, MD, Mayo Clinic in Arizona; Irving Tiong, MD, Humber River Hospital; Steven Weitz, MD, Cardiology Associates of Schenectady; and Alan Wu, PhD, Zuckerberg San Francisco General Hospital. None of these individuals received any compensation for their role in the study.
2.Holmes
DR
Jr , Dehmer
GJ , Kaul
S , Leifer
D , O’Gara
PT , Stein
CM ; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; Writing Committee Members. ACCF/AHA clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association.
Circulation. 2010;122(5):537-557. doi:
10.1161/CIR.0b013e3181ee08edPubMedGoogle ScholarCrossref 4.Mega
JL , Simon
T , Collet
J-P ,
et al. Reduced-function
CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
JAMA. 2010;304(16):1821-1830. doi:
10.1001/jama.2010.1543PubMedGoogle ScholarCrossref 6.Chesebro
JH , Knatterud
G , Roberts
R ,
et al. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge.
Circulation. 1987;76(1):142-154. doi:
10.1161/01.CIR.76.1.142PubMedGoogle ScholarCrossref 9.Oh
I-Y , Park
KW , Kang
S-H ,
et al. Association of cytochrome P450
2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents.
Heart. 2012;98(2):139-144. doi:
10.1136/hrt.2011.227272PubMedGoogle ScholarCrossref 10.Ono
T , Kaikita
K , Hokimoto
S ,
et al. Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional
CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention.
Thromb Res. 2011;128(6):e130-e136. doi:
10.1016/j.thromres.2011.07.028PubMedGoogle ScholarCrossref 11.Zou
J-J , Xie
H-G , Chen
S-L ,
et al. Influence of
CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention.
Eur J Clin Pharmacol. 2013;69(4):771-777. doi:
10.1007/s00228-012-1392-5PubMedGoogle ScholarCrossref 14.Dong
H , Robison
LL , Leisenring
WM , Martin
LJ , Armstrong
GT , Yasui
Y . Estimating the burden of recurrent events in the presence of competing risks: the method of mean cumulative count.
Am J Epidemiol. 2015;181(7):532-540. doi:
10.1093/aje/kwu289PubMedGoogle ScholarCrossref 16.Dayoub
EJ , Seigerman
M , Tuteja
S ,
et al. Trends in platelet adenosine diphosphate P2Y12 receptor inhibitor use and adherence among antiplatelet-naive patients after percutaneous coronary intervention, 2008-2016.
JAMA Intern Med. 2018;178(7):943-950. doi:
10.1001/jamainternmed.2018.0783PubMedGoogle ScholarCrossref 17.Basra
SS , Wang
TY , Simon
DN ,
et al. Ticagrelor use in acute myocardial infarction: insights from the National Cardiovascular Data Registry.
J Am Heart Assoc. 2018;7(12):e008125. doi:
10.1161/JAHA.117.008125PubMedGoogle Scholar 19.Gandhi
S , Zile
B , Tan
MK ,
et al; Canadian ACS Reflective Group. Increased uptake of guideline-recommended oral antiplatelet therapy: insights from the Canadian Acute Coronary Syndrome Reflective.
Can J Cardiol. 2014;30(12):1725-1731. doi:
10.1016/j.cjca.2014.09.011PubMedGoogle ScholarCrossref